Rafael Holdings (RFL) EBITDA (2017 - 2026)
Rafael Holdings' (RFL) quarterly EBITDA came in at -$6.9 million in Q2 2026, down 16.18% year-over-year from -$8.2 million in Q2 2025, and down 3.23% quarter-over-quarter from -$6.7 million in Q1 2026.
Analysis
Rafael Holdings (RFL) EBITDA (2017 - 2026) Analysis & Trends
Rafael Holdings (RFL) has reported EBITDA for 10 consecutive years, with -$6.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA fell 16.18% year-over-year to -$6.9 million in Q2 2026; TTM through Apr 2026 was -$36.4 million, a 79.98% decrease from a year earlier, with the FY2025 full-year figure at -$29.2 million, up 71.59% from the prior year.
- EBITDA was -$6.9 million for Q2 2026 at Rafael Holdings, down from -$6.7 million in the prior quarter.
- Over five years, EBITDA peaked at -$1.6 million in Q1 2022 and troughed at -$93.2 million in Q2 2024.
- A 5-year average of -$10.1 million and a median of -$4.8 million in 2022 frame the typical range for EBITDA.
- Across the five-year window, EBITDA slumped 2992.99% in 2024 and soared 93.65% in 2025, its largest moves.
- Over 5 years, EBITDA stood at -$5.1 million in 2022, then soared by 51.93% to -$2.5 million in 2023, then tumbled by 56.2% to -$3.8 million in 2024, then slumped by 163.81% to -$10.1 million in 2025, then surged by 32.26% to -$6.9 million in 2026.
- The last three EBITDA figures came in at -$6.9 million (Q2 2026), -$6.7 million (Q1 2026), and -$10.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | -6.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -6.87 Mn |
| Jan 31, 2026 | -6.66 Mn |
| Oct 31, 2025 | -10.14 Mn |
| Jul 31, 2025 | -12.76 Mn |
| Apr 30, 2025 | -5.91 Mn |
| Jan 31, 2025 | -6.64 Mn |
| Oct 31, 2024 | -3.84 Mn |
| Jul 31, 2024 | -3.85 Mn |
| Apr 30, 2024 | -93.16 Mn |
| Jan 31, 2024 | -3.14 Mn |
| Oct 31, 2023 | -2.46 Mn |
| Jul 31, 2023 | -2.59 Mn |
| Apr 30, 2023 | -3.01 Mn |
| Jan 31, 2023 | -4.24 Mn |
| Oct 31, 2022 | -5.12 Mn |
| Jul 31, 2022 | -4.89 Mn |
| Apr 30, 2022 | -4.67 Mn |
| Jan 31, 2022 | -1.58 Mn |
| Oct 31, 2021 | -49.52 Mn |
| Jul 31, 2021 | -9.93 Mn |